Average price per bed (asset sales)
$307,000
Q2 FY26
Average price per bed for the 4 facilities sold.
Revolving credit facility outstanding balance repaid
$575 million
Q2 FY26
Portion of net sale proceeds used to repay the outstanding balance under the revolving credit facility.
Share repurchase program capacity increase
$500 million
Q2 FY26
Increase to existing share repurchase program authorized by the Board on August 4, 2026.
Total share repurchase program capacity
$756 million
Q2 FY26
Total capacity for additional repurchases after the $500 million increase.
M&A expenses (Q2 FY26)
$0.7 million
Q2 FY26
Expenses associated with M&A activities for the acquisition of Clinical Solutions Pharmacy, reported in G&A expense.
Employee retention credits (Q2 FY25)
$11.6 million
Q2 FY25
Collection of employee retention credits, including interest, in the prior year quarter.
Adjusted EPS impact from ERCs (Q2 FY25)
$0.08
Q2 FY25
Per share impact of employee retention credits in the prior year quarter.
Initial purchase price for CSP
$148 million
Q2 FY26
Funded with cash on hand and borrowings under the revolving credit facility.
Adjusted EBITDA increase (excluding ERCs)
$17.7 million19.3% YoY
Q2 FY26
Increase in adjusted EBITDA from prior year quarter, excluding employee retention credits.
Weighted average diluted shares outstanding decrease
8.9%YoY
Q2 FY26
Decrease in weighted average diluted shares outstanding as a result of the share repurchase program.
Operating income from ramping facilities
$21.1 million
Q2 FY26
Operating income generated at the 4 facilities ramping up during Q2 FY26.
Net debt to adjusted EBITDA
2.9x
Q2 FY26
Leverage ratio as of June 30, 2026, using trailing 12 months.
Cash on hand
$108.9 million
Q2 FY26
Cash balance as of June 30, 2026.
Borrowing capacity on revolving credit facility (Q2 end)
$273.3 million
Q2 FY26
Additional borrowing capacity on revolving credit facility as of June 30, 2026.
Revolving credit facility outstanding balance (Q2 end)
$280 million
Q2 FY26
Balance outstanding on revolving credit facility as of June 30, 2026.
Total liquidity (Q2 end)
$382.2 million
Q2 FY26
Total liquidity as of June 30, 2026, including cash on hand and borrowing capacity.
Net proceeds from California City and Otay Mesa sales
$1.1 billion
Q3 FY26
Estimated net proceeds after transaction costs and taxes from the sale of California City and Otay Mesa facilities, completed July 2, 2026.
Debt repaid from California City and Otay Mesa proceeds
$608.5 million
Q3 FY26
Total debt paid down using net proceeds from the California City and Otay Mesa sales.
Senior notes due 2027 repaid
$238.5 million
Q3 FY26
Repayment of 4.75% unsecured notes due 2027, part of the $608.5 million debt reduction.
Net proceeds from Midwest Regional and Prairie sales
$522 million
Q3 FY26
Estimated net proceeds after taxes and transaction costs from the sale of Midwest Regional Reception Center and Prairie Correctional facility, completed early August 2026.
Cash on hand (post-sales and debt repayments)
$1 billion
Q3 FY26
Estimated cash on hand after income taxes and debt repayments from all facility sales.
Total debt outstanding (post-sales and debt repayments)
$739.1 million
Q3 FY26
Estimated total debt outstanding after income taxes and debt repayments from all facility sales.
Borrowing capacity on revolving credit facility (post-sales)
$553.3 million
Q3 FY26
Estimated borrowing capacity under revolving credit facility after all facility sales and debt repayments.
Shares repurchased since May 2022
28.1 million
May 2022 - Q2 FY26
Total shares repurchased under the share repurchase program since its authorization.
Aggregate cost of shares repurchased
$444.2 million
May 2022 - Q2 FY26
Total cost of shares repurchased under the share repurchase program.
Average price of shares repurchased
$15.82
May 2022 - Q2 FY26
Average price per share for repurchases since May 2022.
Remaining share repurchase authorization
$755.8 million
Q2 FY26
Amount authorized and available under the share repurchase program, including the increased authorization.
Number of facilities owned (post-sales)
56
Q3 FY26
Number of corrections, detention, and reentry facilities retained after the recent sales.
Design capacity (post-sales)
63,727
Q3 FY26
Total design capacity of retained facilities.
Total square footage (post-sales)
12.3 million
Q3 FY26
Total square footage of retained facilities.
ICE-dedicated facilities owned (post-sales)
9
Q3 FY26
Number of facilities contracted and dedicated fully to ICE among retained assets.
ICE-dedicated facilities design capacity (post-sales)
10,750
Q3 FY26
Design capacity of ICE-dedicated facilities among retained assets.
ICE-dedicated facilities square footage (post-sales)
2.2 million
Q3 FY26
Square footage of ICE-dedicated facilities among retained assets.
Revenue from federal partners growth
27.2%YoY
Q2 FY26
Increase in revenue from federal partners (primarily ICE and U.S. Marshals Service) compared to prior year quarter.
Revenue from ICE growth
$91.3 million51.6% YoY
Q2 FY26
Increase in revenue from ICE compared to prior year quarter.
Revenue from U.S. Marshals Service decrease
$14.1 millionYoY
Q2 FY26
Decrease in revenue from U.S. Marshals Service compared to prior year quarter, partly due to mix shift.
ICE populations in care increase (2025-Q2 2026)
6,00059.6%
Beginning of 2025 - Q2 FY26
Increase in ICE populations in CoreCivic's care from beginning of 2025 through June 30, 2026.
ICE populations in care (Q2 end)
16,197
Q2 FY26
Number of ICE individuals cared for as of June 30, 2026.
Average daily population decrease (QoQ)
1,184QoQ
Q2 FY26
Decrease in average daily population in Q2 FY26 from Q1 FY26, net of increases at activated facilities.
Nationwide ICE detention populations (peak)
70,800
Late January 2026
Historical high for nationwide ICE detention populations.
Nationwide ICE detention populations decrease
10,500
January - April 2026
Decrease in detention populations by early April 2026 due to government shutdown, DHS leadership changes, and redeployment of ICE agents.
Nationwide ICE detention populations (early July)
65,500
Early July 2026
Nationwide ICE detention populations as of early July, showing a rebound.
California City detention facility population
1,674
Q2 FY26
Population at the California City detention facility as of June 30, 2026.
Diamondback correctional facility population
1,522
Q2 FY26
Population at the Diamondback correctional facility as of June 30, 2026.
Midwest Regional Reception Center population
379
Q2 FY26
Population at the Midwest Regional Reception Center as of June 30, 2026, after accepting detainees in March.
Idle corrections and detention facilities
4
Q2 FY26
Number of idle facilities available to meet federal or state demand.
ICE populations in care decline (QoQ)
6.6%QoQ
Q2 FY26
Decline in average daily ICE populations in CoreCivic's care during Q2 FY26 from Q1 FY26.
Nationwide ICE detention populations decline (peak to trough)
14.8%
January - April 2026
Decline in nationwide ICE detention populations from 70,766 at end of January to 60,311 in early April.
Nationwide ICE detention populations increase (April to July)
9%
April - July 2026
Increase in nationwide ICE detention populations from 60,311 in early April to 65,765 in mid-July.
ICE populations in CoreCivic care increase (April to July)
17.7%
April - July 2026
Increase in ICE populations in CoreCivic's care during the same period.
Run rate adjusted EBITDA
$450 million
FY26
Estimated run rate for total adjusted EBITDA, excluding the Prairie facility's full activation impact.
Stock price (current)
$32
Q2 FY26
Approximate trading price of the stock at the time of the call.
Stock price (8x EBITDA multiple)
$41.50
Hypothetical
Hypothetical stock price if trading at 8x EBITDA multiple.
Stock price (9.5x EBITDA multiple)
$48
Hypothetical
Hypothetical stock price if trading at 9.5x EBITDA multiple (20-year average).